Rainbow Childrens Medicare
- P/E
- 45.54
Key Fundamentals
MicrocapHealthcare ServicesHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 17.40%
- Debt to Equity
- 0.54
- EPS (TTM)
- ₹28.10
- Book Value
- ₹168.76
- Market Cap
- —
- P/E (TTM)
- 45.54
- P/B
- 7.58
- ROE
- 15.90%
- Dividend Yield
- 0.28%
- EBITDA
- ₹588 Cr
- 52W High
- ₹1,610.00
- 52W Low
- ₹1,084.00
- Volume
- 0
Peer Comparison
Healthcare › Healthcare Services › Hospitals › Hospital
| ₹8,599.50 | 59.18 | ₹1,22,850 Cr | 13.04 | 0.24% | 21.20% | 17.40% | ₹26,430 Cr | ₹2,171 Cr | |
| ₹927.15 | 61.89 | ₹89,301 Cr | 7.96 | 0.22% | 14.70% | 14.70% | ₹8,712 Cr | ₹1,457 Cr | |
| ₹667.20 | 88.96 | ₹86,479 Cr | 5.34 | 0.00% | 6.64% | 8.30% | ₹11,400 Cr | ₹906 Cr | |
| ₹719.55 | 117.00 | ₹59,927 Cr | 14.91 | 0.44% | 11.30% | 11.60% | ₹4,876 Cr | ₹363 Cr | |
| ₹790.65 | 56.96 | ₹59,706 Cr | 6.03 | 0.13% | 11.20% | 13.40% | ₹9,506 Cr | ₹1,070 Cr | |
| ₹1,931.50 | 48.36 | ₹39,090 Cr | 7.89 | 0.24% | 20.50% | 15.50% | ₹9,072 Cr | ₹816 Cr | |
| ₹1,402.00 | 67.76 | ₹37,618 Cr | 9.52 | 0.04% | 15.20% | 17.40% | ₹4,683 Cr | ₹552 Cr | |
| Rainbow Childrens Medicare (this company) | ₹1,279.60 | 45.54 | ₹12,961 Cr | 7.58 | 0.28% | 15.90% | 17.40% | ₹1,820 Cr | ₹291 Cr |
| Median 8 companies | ₹1,103.38 | 60.54 | ₹59,817 Cr | 7.93 | 0.23% | 14.95% | 15.10% | ₹8,892 Cr | ₹861 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 58
- Good
- Returns, margins, earnings quality 22% weight
- Valuation
- 41
- Weak
- Cheap vs sector & own history 24% weight
- Growth
- 54
- Average
- Sales & profit trajectory 9% weight
- Financial Health
- 26
- Poor
- Solvency, leverage, coverage 9% weight
- Momentum
- 30
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 45
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Company's median sales growth is 22.8% of last 10 years
Weaknesses
1- Stock is trading at 7.44 times its book value
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bearish | 9 | 3 | 7 |
| Oscillators | Neutral | 3 | 3 | 3 |
| Moving Averages | Strong Bearish | 6 | 0 | 4 |
Oscillators
Neutral
Overall
Bearish
Moving Averages
Strong Bearish
Key readings
- RSI (14)
- 53.60
- Neutral
- MACD (12,26,9)
- −28.19
- Bullish
- SMA (50)
- 1,338.79
- Bearish
- SMA (200)
- 1,320.00
- Bearish
As of
Analyst Rating
10 of 10 analysts rate Buy, 0 Hold, 0 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 10Y | +21.96% |
|---|---|
| 5Y | +21.24% |
| 3Y | +13.20% |
| 1Y | +12.34% |
| TTM | +18.34% |
Net profit
| 10Y | +32.43% |
|---|---|
| 5Y | +47.79% |
| 3Y | +9.98% |
| 1Y | +15.57% |
| TTM | +12.36% |
Operating cash flow
| 10Y | +37.81% |
|---|---|
| 5Y | +24.05% |
| 3Y | +8.48% |
| 1Y | +6.06% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | +19.36 pp |
|---|---|
| 5Y | +6.80 pp |
| 3Y | −1.89 pp |
| 1Y | −0.41 pp |
| TTM | −0.86 pp |
Revenue by year
| Mar 2017 | ₹321 Cr |
|---|---|
| Mar 2018 | ₹402 Cr |
| Mar 2019 | ₹543 Cr |
| Mar 2020 | ₹719 Cr |
| Mar 2021 | ₹650 Cr |
| Mar 2022 | ₹974 Cr |
| Mar 2023 | ₹1,174 Cr |
| Mar 2024 | ₹1,297 Cr |
| Mar 2025 | ₹1,516 Cr |
| Mar 2026 | ₹1,703 Cr |
Net profit by year
| Mar 2017 | ₹31.00 Cr |
|---|---|
| Mar 2018 | ₹36.00 Cr |
| Mar 2019 | ₹45.00 Cr |
| Mar 2020 | ₹55.00 Cr |
| Mar 2021 | ₹40.00 Cr |
| Mar 2022 | ₹139 Cr |
| Mar 2023 | ₹212 Cr |
| Mar 2024 | ₹218 Cr |
| Mar 2025 | ₹244 Cr |
| Mar 2026 | ₹282 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Rainbow Childrens Medicare Ltd is a specialized pediatric and maternal healthcare chain with a market cap of ~₹14,980 Cr, trading at a PE of 51.5x and 9.0x book value. The company has delivered a 10-year sales CAGR of 22% and a 10-year profit CAGR of 31%, though recent profit growth has moderated to 11% TTM while ROE stands at 16% for the last year.
- Strong long-term revenue track record with 10-year compounded sales growth of 22%, indicating durable demand in pediatric and maternal healthcare
- Impressive 10-year compounded profit growth of 31%, demonstrating operating leverage and margin expansion over the long term
- Median sales growth of 22.8% over the last 10 years reflects consistent top-line momentum rather than lumpy or one-off gains
- TTM revenue growth of 18% shows continued healthy demand even on a larger base, outpacing many hospital peers
- 5-year ROE averaging 19% indicates efficient capital deployment and solid return generation for shareholders
- Niche positioning in pediatric and maternal care provides a defensible moat with limited listed competition in this specialty segment
- 3-year stock CAGR of 13% shows the market has rewarded the company's operational performance over a medium-term horizon
- PE ratio of 51.5x is significantly elevated compared to the broader hospital sector average of ~30-35x, leaving limited room for execution misses
- Price-to-book of 9.0x is steep, meaning the stock prices in substantial future growth that must materialize to justify current valuation
- Compounded profit growth has decelerated sharply from 44% over 5 years to just 6% over 3 years and 11% TTM, signaling margin or cost pressures
- Last year ROE of 16% has declined from the 5-year average of 19%, suggesting returns on equity may be trending lower as the company scales
- Dividend yield of just 0.24% offers negligible income cushion, making returns almost entirely dependent on capital appreciation
- 1-year stock CAGR of only 2% indicates the market has already begun pricing in the growth slowdown relative to the rich valuation
- 5-year compounded profit CAGR of 44% was partly boosted by a low COVID-era base, which flatters the longer-term growth figures and may not be repeatable
- Expansion into new geographies and bed additions carries execution risk that could temporarily compress margins and weigh on near-term ROE
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Rainbow Childrens Medicare faces near-term leadership uncertainty after losing both its CFO and Chief Strategy Officer within a single week in late August 2026. On the positive side, the company is actively engaging top-tier institutional investors across three major conferences in September. The dual senior exits are a watch item — how quickly the board fills the CFO role and whether strategic initiatives stay on track will determine if this is a temporary disruption or a deeper governance concern.
- CFO and strategy chief exit Aug 25
CFO Vikas Maheshwari resigned effective Aug 31, followed by Chief Strategy and Growth Officer Srinath Metla's departure on Sep 5. Two senior leadership exits within a week raises execution and continuity concerns, with the board still finalizing a CFO replacement.
- Marquee investor conference lineup Sep 11
Rainbow scheduled meetings at Kotak Healthcare Forum, Anand Rathi G-200 Summit, and J.P. Morgan Flagship India Conference during Sep 18-22, 2026. Presence at three top-tier forums signals strong institutional interest and management's proactive investor outreach.
- Investor meetings Sep 18-22 Sep 11
In-person analyst and institutional investor meetings scheduled across three forums during Sep 18-22, 2026, including J.P. Morgan and Kotak events.
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 287 | 333 | 336 | 341 | 330 | 417 | 398 | 370 | 353 | 445 | 445 | 460 | 470 | 548 |
| Expenses | 199 | 215 | 218 | 236 | 236 | 270 | 264 | 255 | 249 | 296 | 298 | 315 | 335 | 378 |
| Operating Profit | 88 | 118 | 118 | 106 | 94 | 147 | 134 | 115 | 104 | 149 | 147 | 145 | 135 | 170 |
| OPM % | 31% | 35% | 35% | 31% | 28% | 35% | 34% | 31% | 29% | 33% | 33% | 31% | 29% | 31% |
| Other Income | 8 | 8 | 9 | 13 | 12 | 11 | 13 | 15 | 20 | 8 | 11 | 4 | 13 | 8 |
| Interest | 15 | 13 | 14 | 17 | 18 | 18 | 18 | 18 | 18 | 19 | 20 | 20 | 21 | 22 |
| Depreciation | 25 | 27 | 28 | 32 | 34 | 35 | 35 | 34 | 34 | 36 | 40 | 41 | 42 | 45 |
| PBT | 56 | 85 | 85 | 69 | 53 | 105 | 94 | 77 | 71 | 102 | 98 | 87 | 84 | 112 |
| Tax % | 25% | 26% | 26% | 26% | 26% | 25% | 27% | 27% | 25% | 26% | 24% | 10% | 26% | 25% |
| Net Profit | 41.49 | 63 | 63 | 51 | 40 | 79 | 69 | 57 | 54 | 76 | 74 | 78 | 63 | 84 |
| EPS (₹) | 4.04 | 6.2 | 6.12 | 5.02 | 3.89 | 7.77 | 6.76 | 5.55 | 5.27 | 7.41 | 7.14 | 7.59 | 5.96 | — |
Sep 2026: from the results filed on 31 Oct 2026, ahead of the full statement, so some rows are blank.
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 169 | 234 | 321 | 402 | 543 | 719 | 650 | 974 | 1,174 | 1,297 | 1,516 | 1,703 | 1,820 |
| Expenses | 128 | 204 | 266 | 332 | 391 | 519 | 485 | 666 | 774 | 865 | 1,022 | 1,155 | 1,245 |
| Operating Profit | 41 | 30 | 55 | 69 | 151 | 201 | 165 | 308 | 400 | 432 | 494 | 548 | 575 |
| OPM % | 24% | 13% | 17% | 17% | 28% | 28% | 25% | 32% | 34% | 33% | 33% | 32% | 32% |
| Other Income | 10 | 16 | 11 | 10 | 8 | 10 | 10 | 19 | 31 | 37 | 51 | 43.79 | 35 |
| Interest | 3 | 3 | 3 | 4 | 42 | 48 | 46 | 56 | 58 | 63 | 77 | 82 | 81 |
| Depreciation | 9 | 18 | 22 | 28 | 60 | 69 | 73 | 83 | 90 | 112 | 138 | 151 | 159 |
| PBT | 38 | 24 | 41 | 47 | 58 | 93 | 56 | 187 | 282 | 295 | 330 | 358 | 371 |
| Tax % | 35% | 28% | 24% | 22% | 22% | 41% | 29% | 26% | 25% | 26% | 26% | 21% | — |
| Net Profit | 25 | 17 | 31 | 36 | 45 | 55 | 40 | 139 | 212 | 218 | 244 | 282 | 290 |
| EPS (₹) | 3.34 | 2.28 | 4.23 | 4.13 | 5.07 | 6.34 | 4.55 | 14.7 | 20.77 | 21.38 | 23.97 | 27.4 | 28.1 |
| Div. Payout % | 7% | 11% | 7% | 12% | 10% | 16% | 0% | 14% | 14% | 14% | 13% | 13% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 9 | 9 | 44 | 44 | 44 | 44 | 94 | 102 | 102 | 102 | 102 |
| Reserves | 166 | 275 | 308 | 307 | 317 | 350 | 391 | 498 | 958 | 1,157 | 1,367 | 1,547 |
| Borrowings | 22 | 24 | 26 | 24 | 476 | 501 | 529 | 592 | 570 | 765 | 764 | 891 |
| Other Liabilities | 34 | 41 | 55 | 73 | 89 | 123 | 116 | 112 | 140 | 146 | 145 | 236 |
| Total Liabilities | 231 | 349 | 399 | 448 | 926 | 1,019 | 1,081 | 1,296 | 1,771 | 2,170 | 2,377 | 2,775 |
| Fixed Assets | 78 | 123 | 174 | 296 | 702 | 702 | 772 | 858 | 931 | 1,253 | 1,398 | 1,756 |
| CWIP | 35 | 31 | 7 | 12 | 23 | 43 | 29 | 6 | 23 | 20 | 28 | 79 |
| Investments | 7 | 2 | 6 | 0 | 3 | 10 | 18 | 22 | 58 | 308 | 571 | 404 |
| Other Assets | 111 | 194 | 212 | 140 | 199 | 265 | 262 | 409 | 759 | 590 | 380 | 535 |
| Total Assets | 231 | 349 | 399 | 448 | 926 | 1,019 | 1,081 | 1,296 | 1,771 | 2,170 | 2,377 | 2,775 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 26 | 17 | 36 | 48 | 127 | 170 | 143 | 224 | 329 | 321 | 396 | 420 |
| Investing | −20 | −107 | −33 | −42 | −117 | −117 | −83 | −175 | −465 | −226 | −268 | −259 |
| Financing | −7 | 93 | −1 | −7 | −9 | −52 | −61 | −44 | 143 | −102 | −118 | −147 |
| Net Cash Flow | −1 | 3 | 1 | −2 | 2 | 2 | −1 | 4 | 7 | −7 | 10 | 14 |
| Free Cash Flow | −35 | −46 | −21 | −103 | 42 | 96 | 67 | 162 | 188 | −32 | 250 | 204 |
| CFO/EBITDA | 95 | 88 | 79 | 88 | 94 | 95 | 102 | 93 | 103 | 95 | 97 | 95 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 11 | 10 | 16 | 14 | 24 | 22 | 25 | 15 | 16 | 20 | 19 | 22 |
| Inventory Days | 39 | 35 | 48 | 36 | 32 | 55 | 36 | 28 | 43 | 53 | 52 | 67 |
| Days Payable | 121 | 107 | 142 | 151 | 197 | 202 | 190 | 121 | 182 | 180 | 170 | 162 |
| Cash Conversion Cycle | −72 | −62 | −79 | −100 | −141 | −124 | −130 | −78 | −123 | −107 | −100 | −73 |
| Working Capital Days | −35 | −36 | −28 | −31 | −26 | −18 | −17 | −16 | 73 | 43 | 19 | 8 |
| ROCE % | 22% | 11% | 14% | 14% | 16% | 16% | 11% | 23% | 24% | 19% | 19% | 17% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Rainbow Childrens Medicare insights
62 extracted metrics across FY15–FY27.
Documents
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q4 FY26 concall · Jun 2026Transcript PPT
- Q4 FY26 concall · May 2026PPT
- Q3 FY26 concall · Feb 2026Transcript PPT Recording
- 27 May 2026
- 27 May 2026
- 29 Sep 2026
- 14 Aug 2025
- 7 Jan 2025
- 6 Dec 2023
- 27 Apr 2023
- General announcements 31 Oct 2026
- General announcements 31 Oct 2026
Frequently Asked Questions about Rainbow Childrens Medicare
What does Rainbow Childrens Medicare Ltd do?
Where is Rainbow Childrens Medicare Ltd (RAINBOW) listed?
Which sector does Rainbow Childrens Medicare Ltd belong to?
What is the PE ratio of Rainbow Childrens Medicare Ltd?
What is the 52-week high and low of Rainbow Childrens Medicare Ltd?
Does Rainbow Childrens Medicare Ltd pay dividends?
What is the Return on Equity (ROE) of Rainbow Childrens Medicare Ltd?
Company Information
Rainbow Children's Medicare Limited operates a multi-specialty pediatric, obstetrics, and gynecology hospital chain in India. The company offers a wide range of services such as newborn and pediatric intensive care, pediatric multi-specialty services, pediatric quaternary care, obstetrics, and gynecology. It is country’s largest pediatric hospital chain with 16 hospitals spread across 6 cities.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/RAINBOW.md for Rainbow Childrens Medicare Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.